As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ERROR 2

Yes! I want to get the latest chemistry news from C&EN in my inbox every week.

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Janssen is paying the South Korean drugmaker Yuhan $50 million to develop its drug candidate lazertinib, which is being tested in people with non-small-cell lung cancers, including ones with brain metastases. Yuhan could receive up to $1.2 billion in future payments from Janssen. Lazertinib is an epithelial growth factor tyrosine-kinase inhibitor. Another drug of that class, AstraZeneca’s Tagrisso, was approved in the U.S. in April and is expected to bring in billions of dollars.

CORRECTION: On Nov. 14, 2018, this story was updated to correct the structure of lazertinib. The original structure was missing a nitrogen.